After 10 years of working together in a CRO focused on cancer trials, the founders of Oncoethix S.A. struck out to in-license and develop novel cancer therapeutics on their own. The company has been operating in stealth mode since its founding in 2007 and is set to begin its second Phase I trial this month.

According to CEO Bertrand Damour and investor Michele Ollier of Index Ventures, a key strength for Oncoethix is the team's cancer drug development expertise obtained while at the CRO.